Magnetic Resonance Imaging and Spectroscopy of the Central Nervous System in Friedreich's Ataxia

Friedreich's ataxia is characterized by progressive alterations in the function of the cerebellum accompanied by an atrophy of the spinal cord. Although the genetic defect responsible for the disease has been identified more than 15 years ago, objective markers of the pathologic process (i.e., biomarkers) that would allow measuring the effects of potential therapies are still lacking. Moreover, it is still unclear how the malfunction of the cerebellum affects the rest of the brain, and understanding the connectivity and neurochemistry of the central nervous system might yield new insights in the understanding of the disease, in addition to providing potential markers.

To address these needs, the investigators aim at utilizing the capabilities of Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS). Using techniques called Diffusion Imaging, resting-state functional MRI, and Proton Spectroscopy (1H MRS), the investigators propose to determine the differences in the connectivity and neurochemistry of the spinal cord and the brain between patients affected by Friedreich's ataxia and healthy controls. The investigators plan on imaging both patients and controls at a 3T magnet, a system that although not yet available in all medical facilities, is becoming standard in most hospitals and clinics. In addition, the investigators plan on scanning the brain of the volunteers at 7T, an ultra-high field system that benefits from higher resolution, yielding images with greater anatomical and functional details. Moreover, the investigators expect that the findings from 7T will benefit the methodology employed at 3T.